AlzGene - Gene overview of all published AD-association studies for FAS
Back Search Methods Disclaimer Credits
 Gene: FAS  (APT1; CD95; FAS1; APO-1; FASTM; ALPS1A;; TNFRSF6; Apo-1 Fas)  Entrez Gene    View on MSGene
 Protein: Fas (TNF receptor superfamily, member 6)  (TNF receptor superfamily, member 6)  ProteinLink
 Chromosome: 10   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Andreoli, 2007
Italy CL  2  (detail)  223
(61%)
C67.9 + 8.3
(-)
70.8 + 8.1
(-)
211
(53%)
72.7 + 8.5
(-)
Negative
Blomqvist, 2005
Overlaps with
Feuk, 2000 
CL  1  (detail)  121
(58%)
C-57.8 + 6.3
(-)
165
(37%)
58.3 + 9.9
(-)
n.a.
Blomqvist, 2005
Sweden CL  1  (detail)  819
(63%)
M-76.2 + 7.1
(-)
240
(59%)
73.2 + 9.3
(-)
Negative
Chiapelli, 2006
Italy CL  2  (detail)  137
(67%)
C-74 + 8
(-)
144
(61%)
67 + 12
(-)
Positive
Corder, 2008
Overlaps with
Blomqvist, 2005
CL  1  (detail)  938
(-)
U--397
(-)
-n.a.
Feuk, 2000
Scotland I CL  1  (detail)  78
(-)
C58.7
(41-65)
-152
(-)
58.1
(31-76)
Positive
Feuk, 2000
Scotland II CL  1  (detail)  87
(-)
M57.5
(-)
-169
(-)
54.8
(44-72)
Positive
Feuk, 2000
Scotland (LOAD) CL  1  (detail)  159
(-)
M78.5
(65-92)
-184
(-)
77
(-)
Negative
Feuk, 2003
Overlaps with
Blomqvist, 2005
CL  6  (detail)  204
(61%)
M--177
(57%)
-Negative
Feuk, 2003
Overlaps with
Feuk, 2000 
CL  20  (detail)  121
(-)
C58.7
(-)
-152
(-)
58.1
(-)
Positive
Giedraitis, 2009
Sweden (ULSAM) CL  2  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Li, 2008
Canada CL  2  (detail)  753
(58%)
C71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Negative
Liang, 2007
USA CL  3  (detail)  483
(63%)
C71.8 + 6
(-)
76.5 + 6.5
(-)
879
(58%)
72 + 6.3
(-)
Positive
Papassotiropoulos, 2006
I (Greece, Italy) CL  1  (detail)  272
(-)
---125
(-)
-Negative
Papassotiropoulos, 2006
II (Switzerland) CL  1  (detail)  174
(-)
---285
(-)
-Negative
Prince, 2001
Overlaps with
Blomqvist, 2005
CL  1  (detail)  204
(61%)
M--186
(58%)
-n.a.
Reiman, 2007
USA, Netherlands CL  1  (detail)  861
(-)
M-74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Rosenmann, 2004
Israel CL  1  (detail)  105
(48%)
C71.4
(49-88)
-104
(48%)
76.8
(62-91)
Negative
Theuns, 2001
Netherlands PO  1  (detail)  111
(-)
C56.7 + 5.4
(-)
-104
(-)
63 + 4.4
(-)
Negative
 Asian
He, 2006
China CL  1  (detail)  509
(62%)
C70.7 + 9.2
(-)
75.6 + 9.8
(46-99)
561
(58%)
69.9 + 8.1
(50-93)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Liang, 2007
USA  3  (detail)  5671521
(67%)
C72.9 + 6.4
(-)
80.1 + 7.1
(-)
974
(56%)
69.9 + 11.2
(-)
Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.